ArticleJournal of pharmaceutical policy and practice2026
Comparison of affordability and availability of antidepressants in China from 2019 to 2022: evidence from national procurement database.
Article in Journal of pharmaceutical policy and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Depression is a widespread mental disorder imposing significant societal burdens. The COVID-19 pandemic exacerbated its prevalence, emphasizing the need for improved access to affordable and effective treatments. This study aims to examine the trends of antidepressant availability and affordability in China from 2019 to 2022 and the role of the National Volume-Based Procurement (NVBP) policy. Methods: Using nationwide daily procurement data of 19 antidepressants encompassing all medical facilities in China from 2019 to 2022, this study adapted the World Health Organization/Health Action International (WHO/HAI) methodology. Availability was defined as the percentage of health facilities procuring specific antidepressant during the year. Affordability was expressed as the number of days at provincial minimum wage to pay for a one-month course of treatment. Temporal variations were described and explored using fractional logit regression, stratified by originator, NVBP involvement, clinical preference, hospital features, and regions. Results: Affordability improved steadily between 2019 and 2022 across most antidepressant groups. The largest improvement occurred among first-line NVBP antidepressants, where the monthly expenditure declined by 0.022-day minimum wage annually. In contrast, affordability changed little for first-line non-NVBP medicines (0.015-day decrease per year) and second-line non-NVBP medicines (0.004-day decrease per year). Availability of originator brands declined annually by 0.8 percentage points, while lowest-priced generics increased by 1.1 percentage points. The largest decline occurred in tertiary private facilities, where availability fell by 3.7 percentage points annually. Improvements in availability were mainly observed in secondary and tertiary public facilities, particularly in the East and Northeast regions. Overall, NVBP first-line medicines had 15.5 percentage points higher availability and greater affordability of 0.167-day minimum wage than other antidepressants. Conclusion: The study highlights the positive influence of the NVBP policy on antidepressant affordability and availability. Regional gaps and facility-specific disparities, though narrowed, still call for policy response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.